Thursday, February 01, 2024 1:48:57 PM
If there's a buyout, it will be based on the market cap at the time. Double the current market cap is roughly the best most companies can do. I don't believe that their is any figure that can be named that isn't achievable in time if the DCVAX-L and Direct prove effective in most solid cancers. Clearly it will take a lot of time, and if the company accepts an offer before that happens, it will be for less.
When we talk about $20 to $40 billion it is very possible to achieve on the strength of DCVAX-L in brain cancer alone, if it is being used in much of the world. I see that possible in a couple years. Perhaps less if major media highlights what the company is doing.
We've all seen other products claiming advancements in GBM, they are true, but nothing close to what DCVAX-L does when combined with other products. It won't be that long before much of the world knows that this is the case. How much you want for NWBO may purely be a case of how long you're willing to wait.
Gary
When we talk about $20 to $40 billion it is very possible to achieve on the strength of DCVAX-L in brain cancer alone, if it is being used in much of the world. I see that possible in a couple years. Perhaps less if major media highlights what the company is doing.
We've all seen other products claiming advancements in GBM, they are true, but nothing close to what DCVAX-L does when combined with other products. It won't be that long before much of the world knows that this is the case. How much you want for NWBO may purely be a case of how long you're willing to wait.
Gary
Recent NWBO News
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 11/26/2025 05:15:34 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
